Liver cancer, the third most common cause of cancer-related deaths worldwide, is the fifth most common type of cancer. Resection patients typically have a low cure rate. Sorafenib is the only drug approved by the US Food and Drug Administration to treat advanced HCC, but it comes with substantial side effects, including a high risk of haemorrhaging. These restrictions necessitated the urgent need for innovative preventative and therapeutic approaches to managing this illness.